Wolverine Asset Management LLC Gilead Sciences, Inc. Transaction History

Wolverine Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $117,609 - $128,505	-1,853 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $27,540 - $31,423	-459 Reduced 19.85%	1,853 $119,000
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $203,543 - $231,928	-3,593 Reduced 60.85%	2,312 $134,000
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $366,700 - $461,062	5,905 New	5,905 $373,000
Q1 2020 May 13, 2020	SELL	$62.63 - $80.22 $1,189 - $1,524	-19 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $20,280 - $26,465	-335 Reduced 94.63%	19 $1,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $29,652 - $32,830	-416 Reduced 54.03%	354 $27,000
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $8.13 Million - $9.92 Million	-111,659 Reduced 99.32%	770 $58,000
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $7.69 Million - $9.03 Million	108,129 Added 2514.63%	112,429 $8.05 Million
Q2 2017 Aug 14, 2017	BUY	N/A	4,300	4,300 $304,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.